My research interests are focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and approaches for risk prediction, population stratification, targeted screening, cancer prevention and cost-effectiveness analyses.
A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol (2019). PMID: 31580391
Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation-testing in unselected general-population women. J Natl Cancer Inst (2018); 110(7):714-725. PMID: 29361001
Cost effectiveness of population screening for BRCA mutations in Ashkenazi-Jewish women compared to family-history based testing. J Natl Cancer Inst (2015); 107(1):380. PMID: 25435542
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomised controlled trial. J Natl Cancer Inst (2015); 107(1):379. PMID: 25435541
My research is focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and precision medicine approaches for risk prediction, population stratification, targeted screening, cancer prevention (including surgical prevention) and management of familial gynaecological cancer. I have a keen research interest in health economic issues related to these areas.
I am Chief Investigator (CI) on PROTECT (PROTECT: Population based Germline testing for Early detection and Cancer Prevention); PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) trial; DETECT-2 (Direct to Patient testing at Cancer diagnosis for Precision Prevention) study; PRESCORES (Prevention of endometrial cancer: Utility scores of risk-reducing strategies); JHCR (Jewish Hereditary Cancer Research); PROMISE Feasibility study (pilot general population testing and personalised ovarian cancer risk prediction study); SIGNPOST (SystematIc GeNetic testing for Personalised Ovarian cancer Therapy) study and RRESDO (study evaluating attitudes towards early salpingectomy) studies; Co-PI of GCaPPS trial (population based BRCA testing RCT in the Jewish population); Co-Lead for UKCOGS (UK COVID and Gynaecological Cancer Study); Co-lead for SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management programme. I have worked on ovarian cancer screening trials (UKCTOCS, UKFOCSS and ALDO).
Academic Roles (select):
Clinical Roles (select):
Other roles:
Clinical Interests: Ovarian cancer radical debulking surgery, Sentinel node biopsy, Management of women at high risk of gynaecological cancer
Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study. Sobocan M, Chandrasekaran D, Sideris M et al. BJOG (2023) (2)
https://www.ncbi.nlm.nih.gov/pubmed/37752678
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial Menon U, Gentry-Maharaj A, Burnell M et al. The Lancet Oncology (2023) 24(7) 1018-1028
Patient-reported quality of life following prophylactic surgery for breast and ovarian cancer prevention: Response. Wei X, Oxley S, Sideris M et al. Am J Obstet Gynecol (2023) (2)
https://www.ncbi.nlm.nih.gov/pubmed/37659746
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: A multi-national observational study Morgan RD, Clamp AR, Barnes BM et al. International Journal of Gynecological Cancer (2023) 33(7) 1253-1259
Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in India Pillai D, Narayan J, Gentry-Maharaj A et al. Cancers (2023) 15(7)
The avoiding late diagnosis of ovarian cancer (ALDO) project; A pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 Philpott S, Raikou M, Manchanda R et al. Journal of Medical Genetics (2023) 60(7) 440-449
Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments Laforêts F, Kotantaki P, Malacrida B et al. iScience (2023) 26(7)
Abstract LB195: Immunotherapies that repolarize macrophages and CD4 T cells enhance the effect of chemotherapy in high-grade serous ovarian cancer Elorbany S, Berlato C, Carnevalli L et al. Cancer Research (2023) 83(10) lb195-lb195
Abstract 4551: Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer: understanding the contribution of malignant cells Malacrida B, Elorbany S, Maniati E et al. Cancer Research (2023) 83(10) 4551-4551
Abstract 5913: Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments Laforets F, Kotantaki P, Malacrida B et al. Cancer Research (2023) 83(10) 5913-5913
For additional publications, please click hereAcademic Clinical Lecturer
Senior Research Fellow
Clinical Trials Coordinator
PhD Students
Honorary Research Fellows
I was appointed as Professor of Gynaecological Oncology at Wolfson Institute of Population Health, Queen Mary University of London in Sep 2019. I joined Barts Cancer Institute, Queen Mary, as a Clinical Senior Lecturer in June 2015. I have worked as a consultant Gynaecological Oncologist at Barts Health NHS Trust from June 2015. From 2014- 2015 I worked as a Locum Consultant Gynaecological Oncologist at Barts Health and Honorary Senior Lecturer at University College London, UK. I completed a PhD in gynaecological oncology at UCL, followed by a NIHR ACL Fellowship and subspecialty training in gynaecological oncology from UCLH and Bart's Hospital.
I am Co-Lead for Cancer Prevention Unit, Wolfson Institute of Population Health, Queen Mary; and Co-Lead for Cancer Prevention (Theme-1), CRUK Barts Centre. I was awarded an NHS Innovation Accelerator Fellowship in March 2019. I am Chief Investigator (CI) on PROTECT (PROTECT: Population based Germline testing for Early detection and Cancer Prevention); PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) trial; DETECT-2 (Direct to Patient testing at Cancer diagnosis for Precision Prevention) study; PRESCORES (Prevention of endometrial cancer: Utility scores of risk-reducing strategies); JHCR (Jewish Hereditary Cancer Research); PROMISE Feasibility study (pilot general population testing and personalised ovarian cancer risk prediction study); SIGNPOST (SystematIc GeNetic testing for Personalised Ovarian cancer Therapy) study and RRESDO (study evaluating attitudes towards early salpingectomy) studies; Co-PI of GCaPPS trial (population based BRCA testing RCT in the Jewish population); Co-Lead for UKCOGS (UK COVID and Gynaecological Cancer Study); Co-lead for SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management programme. I have worked on ovarian cancer screening trials (UKCTOCS, UKFOCSS and ALDO).
I lead the Barts Health Women’s Precision Prevention Service, Chair the London Cancer High Risk Gynaecological Cancer MDT, Member National Cancer Programme Early Diagnosis Task & Finish group, Topic Advisor (Clinical Lead) for the NICE Guideline on Familial Ovarian Cancer, and Clinical Lead for Gynaecological Cancer North Thames GLH. I am scientific advisor to BRCA Umbrella and GO Girls, Chair the Independent Advisory Committee of the Mermaid Project (Demark) and serve on number of oversight committees.
I am actively involved in gynaecological oncology training issues. I helped develop and establish ENYGO (European Network of Young Gynaecological Oncologists) from its inception and have led/undertaken a number of initiatives for European and International trainees in gynaecological oncology. I have served as the president of the European Network of young Gynaecological Oncologists (ENYGO) and a member of the European Society of Gynaecological Oncology (ESGO) council (2011-2013). I am the Integrated Academic Training Programme Director and lead for the RCOG Advanced Professional Module (APM) in Clinical Research for London Specialty School of Obstetrics & Gynaecology, Health Education England. I am the deputy director of the Barts Health RCOG gynaecological oncology training programme and Mentor for the IGCS Gynecologic Oncology Global Curriculum & Mentorship Program.
Previous posts
Education & Qualifications